Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) registered a -4.38% decrease, still its new closing price is 47.59% up from the company’s 1 year high of 7.80.It posted -12.24% losses in previous 5 sessions and is now the subject of 5 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 9 stock analysts following this company have an average price target at $7.21, with individual PT in the $4.00-$11.00 range. The shares moved at $4.59, implying that brokerage firms see shares gaining about 30.03% in twelve months time.

Keryx Biopharmaceuticals, Inc. (KERX) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a -21.67% fall year to date. A Chief Medical Officer at Keryx Biopharmaceuticals, Inc. (KERX) offloaded shares in a transaction closed on Monday January 23, 2017. Neylan John F. sold 1,428 shares in the company at $5.39 each and collected $7,001 in proceeds. Neylan John F. now owns 90,128 shares in the company after this transaction. A VP and General Counsel in the company, Adams Brian, disclosed a transaction on Tuesday January 17, 2017 that ended up generating $7,001 from the sale of 1,265 shares at $6.24 per share.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Upcoming Results on Tap

Keryx Biopharmaceuticals, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.18 in that period. Sales during the quarter are predicted to arrive at $11.05 million.

Earnings surprise history: Last quarter, the company posted approximately $6.34 million in revenue and EPS of $-0.39. The mean forecast was for $5.45 million and $-0.20 a share, respectively. One quarter earlier, revenue for the stock was at $9.29 million, with earnings at $-0.42/share.

Keryx Biopharmaceuticals, Inc. (KERX) Brokerage Update

Keryx Biopharmaceuticals, Inc. (KERX) is in Citigroup’s research list so their analyst rating change is noteworthy. These shares were upgraded to Neutral from Sell by Citigroup, according to news reported on Wednesday January 11, 2017.Another important research note was issued by Maxim Group on Wednesday November 09, 2016.The firm upgraded KERX to Buy from Hold. Over the last six months and over the last three months, the shares of Keryx Biopharmaceuticals, Inc. (KERX), have changed -37.64% and 1.77%, respectively.